Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tobramycin
Drug ID BADD_D02232
Description Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms.[A232294] Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Indications and Usage For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
Marketing Status Prescription; Discontinued
ATC Code J01GB01; S01AA12
DrugBank ID DB00684
KEGG ID D00063
MeSH ID D014031
PubChem ID 36294
TTD Drug ID D07BCT
NDC Product Code 47335-171; 68788-7252; 65162-914; 63187-973; 51927-0226; 68083-312; 49502-401; 0078-0630; 68071-2272; 51927-2375; 53002-9230; 60760-583; 36000-242; 17478-290; 61314-643; 61919-598; 70644-899; 55700-747; 0404-7196; 76420-092; 0078-0494; 0093-4085; 70518-1370; 45865-427; 68180-962; 20076-2006; 42513-0011; 81861-0030; 49502-346; 0065-0644; 51846-1012; 68083-241; 0078-0813; 68071-4537; 51552-1520; 24492-850; 67457-473; 72266-163; 24208-290; 11014-0233; 50090-3569; 67457-428; 0065-0643; 50090-0486; 59651-129; 57885-0002; 68083-254; 53002-9232; 68083-374; 67877-678; 71205-101; 53002-9231; 61919-642; 36000-244; 13985-604; 45865-119; 39822-0412; 63187-024; 70700-173; 49502-345; 11722-073; 72266-196; 68083-253; 17478-340; 0093-3750; 63187-902; 10122-820; 53002-9233; 70069-131
Synonyms Tobramycin | Nebramycin Factor 6 | Tobramycin Sulfate | Sulfate, Tobramycin | Obracin | Tobracin | Brulamycin | Nebcin | Nebicin
Chemical Information
Molecular Formula C18H37N5O9
CAS Registry Number 32986-56-4
SMILES C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephropathy toxicBeta-hexosaminidaseP87258Not Available3820859; 3573418; 2352376; 6519582
Nephropathy toxicLysozyme CP61626T105863820859; 3573418; 2352376; 6519582
Nephropathy toxicL-lactate dehydrogenase A chainP00338T150533820859; 3573418; 2352376; 6519582
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin abnormal13.01.05.0110.000619%Not Available
Haemoptysis24.07.01.006; 02.01.02.006; 22.02.03.0040.009903%Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.0020.001238%Not Available
Hip fracture15.08.03.001; 12.04.01.0010.000619%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.0030.005261%
Hypertension24.08.02.001--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.003--
Hypocalcaemia14.04.01.004--
Hypoglycaemia14.06.03.001; 05.06.03.0010.000928%
Hypokalaemia14.05.03.002--
Hypomagnesaemia14.04.02.001--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Hypouricaemia14.09.01.006--Not Available
Hypoxia22.02.02.0030.001547%
Immune system disorder10.02.01.001--Not Available
Immunoglobulins increased13.06.05.005--Not Available
Infection11.01.08.0020.002503%Not Available
Influenza22.07.02.001; 11.05.03.0010.002166%Not Available
Influenza like illness08.01.03.0100.000928%
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Instillation site pain08.02.01.008; 12.07.01.008--Not Available
Interstitial lung disease10.02.01.033; 22.01.02.003--Not Available
Intestinal obstruction07.13.01.0020.001238%Not Available
Irritability19.04.02.013; 08.01.03.011--
Joint dislocation15.01.07.002; 12.04.02.0070.000619%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages